Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Retained Earnings: 2010-2024

Historic Retained Earnings for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to -$561.4 million.

  • Altimmune's Retained Earnings fell 15.59% to -$622.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$622.1 million, marking a year-over-year decrease of 15.59%. This contributed to the annual value of -$561.4 million for FY2024, which is 20.38% down from last year.
  • Altimmune's Retained Earnings amounted to -$561.4 million in FY2024, which was down 20.38% from -$466.3 million recorded in FY2023.
  • In the past 5 years, Altimmune's Retained Earnings registered a high of -$186.4 million during FY2020, and its lowest value of -$561.4 million during FY2024.
  • Over the past 3 years, Altimmune's median Retained Earnings value was -$466.3 million (recorded in 2023), while the average stood at -$468.5 million.
  • Data for Altimmune's Retained Earnings shows a maximum YoY plummeted of 57.26% (in 2021) over the last 5 years.
  • Over the past 5 years, Altimmune's Retained Earnings (Yearly) stood at -$186.4 million in 2020, then tumbled by 57.26% to -$293.2 million in 2021, then decreased by 28.90% to -$377.9 million in 2022, then dropped by 23.41% to -$466.3 million in 2023, then decreased by 20.38% to -$561.4 million in 2024.